Əsas səhifə

Çap

Əks əlaqə

İnfo
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas

Mündəricat

Selective estrogen receptor modulators (SERMs) for uterine leiomyomas

Sübutlu məlumatların xülasələri
17.02.2016 • Sonuncu dəyişiklik 17.02.2016
Editors

Selective estrogen receptor modulators may not reduce the size of fibroids or improve clinical outcomes in women with uterine leiomyomas.

A Cochrane review included 3 studies with a total of 215 subjects. Comparison interventions included no treatment, Poly vitamins, and leuprolide acetate depot plus raloxifene versus leuprolide plus placebo tablet. There was a tendency towards fibroid reduction with selective estrogen receptor modulators (SERMs), although this was not significant in all studies. All three studies mentioned adverse reactions but no detailed data were acquired in the included studies.

Comment: The quality of evidence is downgraded by study quality (unclear allocation concealment and by imprecise results) few studied patients.

Ədəbiyyat

  1. Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2007;(4):CD005287 [Review content assessed as up-to-date: 11 April 2012] .